Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Trimeris Inc. said it is the target of a patent infringement suit by Novartis Vaccines and Diagnostics Inc. related to manufacture and sale of HIV fusion inhibitor Fuzeon.

In a filing with the Securities and Exchange Commission, Trimeris said it was informed Nov. 20 that Novartis filed suit against Hoffman-La Roche Inc., Roche Laboratories Inc., Roche Colorado Corp., and F. Hoffman-La Roche Ltd. and the company alleging infringement of an HIV-related Novartis patent.

Want to continue reading?
Become a Free ALM Digital Reader.

Benefits of a Digital Membership:

  • Free access to 1 article* every 30 days
  • Access to the entire ALM network of websites
  • Unlimited access to the ALM suite of newsletters
  • Build custom alerts on any search topic of your choosing
  • Search by a wide range of topics

*May exclude premium content
Already have an account?


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.